Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
STAC3 binding to CaV1.1 II-III loop is nonessential but critically supports skeletal muscle excitation-contraction coupling
Wietske E. Tuinte, Enikő Török, Petronel Tuluc, Fabiana Fattori, Adele D’Amico, Marta Campiglio
Wietske E. Tuinte, Enikő Török, Petronel Tuluc, Fabiana Fattori, Adele D’Amico, Marta Campiglio
View: Text | PDF
Research Article Muscle biology Neuroscience

STAC3 binding to CaV1.1 II-III loop is nonessential but critically supports skeletal muscle excitation-contraction coupling

  • Text
  • PDF
Abstract

Skeletal muscle excitation-contraction (EC) coupling depends on the direct coupling between CaV1.1 on the sarcolemma and ryanodine receptor (RyR1) on the sarcoplasmic reticulum. A key regulator of this process is STAC3, a protein essential for both the functional expression of CaV1.1 and its conformational coupling with RyR1. Mutations in Stac3 cause STAC3 disorder, a congenital myopathy characterized by muscle weakness. STAC3 interacts with CaV1.1 in 2 key regions: the II-III loop and the proximal C-terminus. While the II-III loop has been previously found to be essential for skeletal muscle EC coupling, here we demonstrated that the interaction between STAC3 and the proximal C-terminus is necessary and sufficient for CaV1.1 functional expression and minimal EC coupling. In contrast, the interaction with the II-III loop is not essential for EC coupling, though it plays a facilitating role in enhancing the process. Supporting this finding, we identified a patient with STAC3 disorder carrying a mutation that deletes the domain of STAC3 involved in the II-III loop interaction. Collectively, our results established that STAC3 binding to CaV1.1 C-terminus is essential for its functional expression, whereas STAC3 interaction with the II-III loop serves to enhance the conformational coupling with RyR1.

Authors

Wietske E. Tuinte, Enikő Török, Petronel Tuluc, Fabiana Fattori, Adele D’Amico, Marta Campiglio

×

Figure 4

STAC3-NT supports functional expression of CaV1.1 and the conformational coupling with RyR1.

Options: View larger image (or click on image) Download as PowerPoint
STAC3-NT supports functional expression of CaV1.1 and the conformational...
(A) Cartoon showing the STAC3 fragments reconstituted in CaV1.1/Stac3-KO myotubes together with CaV1.1 and relative representative charge movement (QON), calcium current, and calcium release traces. (B) Average Q-V relationships (left) and QON max (right). One-way ANOVA F (3, 33) = 3.312, *P = 0.0319. The stars on the graph represent the results of Dunnett’s multiple-comparison test: CaV1.1 *P = 0.0368, STAC3-CT *P = 0.0322. CaV1.1 n = 8, STAC3 n = 12, STAC3-NT n = 8, STAC3-CT n = 9. (C) Average peak I-V relationships (left) and peak current amplitudes (right). One-way ANOVA F (2, 40) = 8.435, ***P = 0.0009, Dunnett’s multiple-comparison test ***P = 0.0006. STAC3 n = 25, STAC3-NT n = 8, STAC3-CT n = 12. (D) Average peak change in fluorescence normalized by baseline (ΔF/F0) as a function of test potential (left) and ΔF/F0 peak values (right). One-way ANOVA F (2, 40) = 13.49, ****P < 0.0001. Dunnett’s multiple-comparison test: STAC3-NT **P = 0.0054, STAC3-CT ****P < 0.0001. STAC3 n = 25, STAC3-NT n = 8, STAC3-CT n = 12. Two STAC3-CT ΔF/F0 peak values in the red box were outliers and not considered in the statistical analyses.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts